Allegiance Equity Corporation Shareholder Update
23 Septembre 2011 - 9:17PM
PR Newswire (Canada)
TORONTO, Sept. 26, 2011 /CNW/ - Allegiance Equity Corporation
(www.allegianceequity.com) is pleased to provide a shareholder
update. Update on RELIEVA(TM) and Clinical Trials with DSE
Healthcare Solutions L.L.C. DSE Healthcare Solutions L.L.C.,
Edison, New Jersey is in the final stages of its clinical trial
with a new formulation for Relieva. The clinical trial with the new
formulation will be completed shortly where all expenses were
assumed by DSE Healthcare. DSE Healthcare Solutions is successful
in the marketing of health care, medical and consumer products to
mass food and drug market. DSE Healthcare Solutions was founded by
very experienced former managers of one of the world's largest
pharmaceutical and health care companies. Robert C. Stites, the CEO
and one of the founders of DSE, was previously President and Chief
Operating Officer of Johnson & Johnson Products. Allegiance is
also in discussions with a number of companies including two
multinationals for licensing Relieva, one of which is one of the
largest consumer goods companies in the world and the other a
Spanish Pharmaceutical Company. These companies have been testing
and experimenting as part of their due diligence with Relieva and
Psoberine extract Relieva(TM) made with Psorberine(TM) an
anti-inflammatory, antibacterial product for the treatment of
psoriasis and atopic dermatitis. Relieva(TM) provides immediate
relief for itching, irritation and inflammation associated with
almost all problem skin conditions with ZERO toxicity and
Irritation. Relieva is a premium skin care product for everyday use
for healthy skin. However that is only half the story. Relieva and
Psorberine have a number of significant distinct competitive
advantages over existing psoriasis treatments including the world's
largest selling psoriasis treatment. Other psoriasis treatments
(including the leader) may lose their effectiveness over time as
the disease builds up tolerability to other treatments this is not
the case with Relieva that has a zero irritancy and toxicity
rating, with no known health risks or side effects. Global
Psoriasis Drugs Market to Exceed $7.3 Billion Dollars by 2015,
according to new reports by "Global Industry analysts Inc." with no
satisfactory treatment in sight Allegiance Equity and Fernando
Pisano from Simcoe Asia Group (SA Group) Fernando
Pisano CEO of SA Group commented,"SA Group is excited to represent
Allegiance's outstanding products. Relieva Psoriasis cream has
over 4 million dollars of research behind it and is one of the best
OTC products available to the public. CinGx is a new and
outstanding ingredient for food products targeting diabetes
sufferers that could revolutionize the food industry, like Stevia
and Aspartame have. We expect to see them as an additive to many
existing product lines and many new ones". Pisano further noted
that, "With over 366 million people living with diabetes and over
125 million people living with Psoriasis, and almost that many with
other skin ailments like Eczema rashes and skin allergies,
Allegiance's products address a very large market that we look
forward to penetrating." "This alliance will be beneficial to
Allegiance in many ways," stated David Solomon, President of
Allegiance Equity. "The marketing and licensing abilities of SA
Group are impressive, not to mention their abilities to introduce
potential joint ventures and endorsements that will add to the
marketing efforts on a global scale," concluded David
Solomon. "Allegiance Equity is extremely fortunate to have
such strong partners as Nealanders and SA Group, which is a
testimony to the quality of the Company's products and validates
the growing demand for these products," commented David Solomon
Allegiance Terminates Agreement with Premier Selling Technologies
Inc (Premier) Allegiance has terminated its agreement dated May
2(nd) 2011 with Premier previously announced on May 3(rd )2011 as a
result of Premier`s breach of contract and its failure to meet its
obligations hereunder PRIVATE PLACEMENT Allegiance previously
announced a proposed private a private placement to raise up to
$250,000 by sale of common shares to be priced within the context
of the market on August 26(th) ,2011 and will not proceed withthis
placement However Allegiance will proceed and close a private
placement to be priced wiyhin the context of the market within the
next 15 days. Interest of Management Notice of Intention to
Distribute Palm American Investments Inc. is the controlling
shareholder of Allegiance holding 1,867,831 common 1, shares. Palm
American Investment Inc is controlled by David Solomon, Marilyn
Bloovol and members of their family, Corporations controlled by
Marilyn Bloovol and David Solomon, directors and officers of
Allegiance may participate in the private placement, directly or
indirectly through corporations controlled by them. Palm American
filed a Notice of Intention on September 20th to sell up to 500,000
common shares in the market from time to time or by way of private
sale ABOUT ALLEGIANCE Allegiance targets billion dollar markets
having clearly identified product deficiencies and dissatisfied
patients who suffer widespread diseases and conditions including
diabetes, cholesterol, Alzheimer`s and Dementia and arthritis.
Allegiance's strategy utilizes leading-edge scientific technology
to create valuable, proprietary and effective natural treatments,
recognized as safe and effective by North American regulatory
authorities, at a fraction of the cost and time it takes to develop
a prescription drug. Allegiance then obtains patents and regulatory
approvals. There are presently 7,061921 common shares of Allegiance
issued and outstanding. Additional information relevant to the
Company's activities, including the Company's press releases can
found on SEDAR at www.sedar.com The TSX Venture Exchange has not
reviewed and does not accept responsibility FOR THE ADEQUACY OR
ACCURACY FOR HIS PRESS RELEASE, WHICH HAS BEEN PREPARED BY
MANAGEMENT. Allegiance Equity Corporation CONTACT: on Allegiance
Equity Corporation, contact David Solomon,President, bytelephone at
(416) 630 1221 or (647) 271-7208, or
dsolomon79@gmail.comwww.allegianceequity.com
Copyright
(TSXV:ANQ)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
(TSXV:ANQ)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about (TSX Venture Exchange): 0 recent articles
Plus d'articles sur Allegiance Equity Corp